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Bromo-deoxy-uridinemicroRNAs (miRs) are small non-protein-coding RNAs, able to post-transcriptionally regulate many genes and
exert pleiotropic effects. Alteration ofmiR levels in tissues and in the circulation has been associatedwith various
pathological and regenerative conditions. In this regard, tissue engineering of cardiac and skeletal muscles is a
fascinating context for harnessing the complexity of miR-based circuitries and signals. In this review, we will
focus on miR-driven regulation of cardiac and skeletal myogenic routes in homeostatic and challenging states.
Furthermore, we will survey the intriguing perspective of exosomal and circulating miRs as novel paracrine
players, potentially useful for current and future approaches of regenerative medicine for the striated muscles.
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Striatedmuscles constitute approximately 40% of our bodymass and
are responsible for constant blood pumping, i.e. the cardiac muscle, and
for posture and movements, i.e. the skeletal muscles. Several diseases
chronically affect both cardiac and skeletal muscles, includingmuscular
dystrophies (MDs) [1], cancer cachexia [2] and metabolic disorders [3].
At present, regenerative treatments are not yet available for the clinical
care of striated muscle disorders, in spite of increasing demand and
global burden [4]. Therefore, the ﬁeldwould beneﬁt from a comprehen-
sive understanding of cellular and molecular mechanisms governing
generation and regeneration of both muscle types.
Over the last years, the static notion of post-mitotic tissues is
under continuous re-shaping for striated muscles. Many ﬁndings have
disclosed the possibility of (re)generating adult myocytes by means of
stem cells or progenitors with different origins and potency [5]. Although
the relevance for steady and pathological states is still ﬁercely debated
[6,7], it is noteworthy that the study of (re)generation mechanisms has
fueled a deeper venture into the complexity of muscle formation.
In this context, the post-transcriptional control exerted bymicroRNAs
(miRs) constitutes one of the most remarkable layers of complexity [8].
MiR-gene feedback circuitries ﬁnely orchestrate cell-based engineering
for striated muscle repair [9]. Also, it has recently become evident that
miRs can be released in the circulation, probably cross-signaling on
both short-range and long-range [10]. Thus, this review will focus on
the miR-mediated complex regulation of myogenic routes in cardiac
and skeletal muscles. In addition, it will report on the intriguing perspec-
tive of vesicular and non-vesicular circulating miRs (circ-miRs) with
respect to challenging conditions of striated muscles.
2. Biogenesis of miRs
MiRs are conserved, ~22 nt-long, non protein-codingRNAmolecules
regulating gene expression at post-transcriptional stage. MiR-based
gene regulation is intrinsically complex, considering that one transcript
is targetable by different miRs and one miR can target different tran-
scripts [11]. Currently, 1920 murine and 2603 human mature miR en-
tries are reported in the miRbase sequence repository (mirbase.org;
March 2015). MiR-encoding genes are present in the genome as
intergenic clusters or individual transcriptional units. In both cases,
their expression is under the control of promoters and enhancers with
similar characteristics and regulation to those for protein-coding
genes [12]. Several miRs, however, are embedded in the intronic
sequences of other genes (miRtrons) and are then co-transcribed ac-
cordingly with the encompassing genes [13]. Following the canonical
pathway, miR genes are generally transcribed by RNA polymerase II
into primary transcripts of several hundred nucleotides (pri-miRs),bearing secondary hairpin structures and undergoing 5′ capping and
3′ polyadenylation [14]. In few cases, miR genes are transcribed by
RNApolymerase III [15].While still inside the nucleus, themicroproces-
sor complex, formed by the RNase-III Drosha and its co-factor Dgcr-8,
cleaves the pri-miRs into ~70 nt-long precursor molecules (pre-miRs)
[16]. Exportin-5, a Ran-GTP-dependent nuclear export protein, shuttles
the pre-miRs into the cytosol [17]. Once in the cytosol, pre-miRs are
further cleaved in ~22 nt-long double-strandedmolecules by a complex
that includes another RNase-III, Dicer, in combination with its RNA-
binding cofactor, Tbrp [18]. After Dicer-mediated maturation, miRs are
loaded on the RNA-induced silencing complex (RISC) as single strands.
Mature miR duplexes are in fact separated in guide and passenger
strands. The guide strand (miR) usually presents the weakest base pair
at 5′ and is preferentially loaded on theRISC complex,whereas the com-
plementary passenger strand (miR*) is preferentially degraded [19,20].
The RISC complex includes Argonaute proteins, such as Ago-2, and
targets the miR to its messenger RNA (mRNA) targets. Also, Ago-2-
binding protein, Gw-182, shuttles the miR-loaded, active RISC complex
to discrete foci in the cytoplasm, called processing bodies (P-bodies),
where several enzymes are available formRNAdecapping, deadenylation
and degradation [21]. Although the exact mechanisms are still unclear, it
seems that miRs generally recognize the 3′ untranslated region (3′-UTR)
of target mRNAs. According to the binding complementarity of the seed
sequence (generally comprised between nt1 and nt9 at miR 5′ end),
miRs repress gene expression by targeting the mRNA for degradation
(complete match) or by mediating translation inhibition (incomplete
match). The latter is achieved through various mechanisms, including
RISC-mediated destabilization of ribosomal assembly or translation
continuation [22] (Fig. 1).
Non-canonical processing of miR transcripts, typical for miRtrons,
relies on direct processing of the pre-miRs during intron splicing of
the harboring gene mRNA. Other microprocessor-independent sources
of pre-miRs encompass small nucleolar RNAs (snoRNAs), transfer RNA
precursors (tRNAs) and short hairpin RNAs (shRNAs) [23].
2.1. Modulation of miRs
Many factors regulate miR biogenesis and hence affect downstream
miR-mediated gene repression. RNA editing of pri-miRs or pre-miRs by
deaminases [24], or through 3′ uridylation, can inﬂuence Drosha- or
Dicer-dependent processing steps. Also, abundance of Ago-2 or agonist
proteins directly affects RISC activity levels. Another important aspect of
intrinsic miR regulation, albeit still rather obscure, consists of turnover
and degradation. After mRNA targeting and in the presence of still
unknown signals, the miR guide strand is released and degraded. The
turnover process of miRs still remains largely unknown. Average half-
life of miRs has been estimated to ~119 h [25] and exoribonucleases,
Fig. 1. Biogenesis and trafﬁcking of miRs. Once processed bymicroprocessor and Dicer complexes, miRs are loaded on the RISC complex, or are shuttled to exosomes or non-vesicular car-
riers for paracrine signaling, or shed into the circulation. MiRs are modulated through miR-mimics, antagomiRs and miRs that are shuttled by exosomes, protein- and HDL-carriers.
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systematic studies are needed to shed light on the selectivemechanisms
regulating miR turnover.
2.2. Vesicular and non-vesicular trafﬁcking of miRs
Besides operating intracellularly, miRs can be released from the pro-
ducing cells in the surrounding areas or in the circulation. Intriguingly,
circulating miRs (circ-miRs) are traceable in plasma or serum and ap-
pear resistant to harsh conditions such as RNase activity, pH changes,
boiling, freeze-thawing and storage at room temperature [27]. Carriers
or membranous vesicles generally protect the circ-miRs in the blood-
stream. Non-vesicle carriers encompass protein complexes, including
Ago-2 and Nucleophosmine-1, and lipoprotein complexes, such as
high-density lipoproteins (HDLs) [28]. Among the vesicle-based car-
riers, exosomes are emerging as important regulators of long-range
miR shuttling [29]. Exosomes are small vesicles (40–100 nm diameter)
that enclose their cargo with a lipidic bi-layer and are generated from
intracellular multivesicular bodies [30]. Exosomes mature through a
still unknown process, most likely at the interface with the Golgi reticu-
lum, and then shed from the plasma membrane. Exosomes typically
carry heat-shock proteins Hsp-60/70 in the lumen, and present
tetraspanins, such as CD9/63/81, and tissue-speciﬁcmembrane proteins
on the surface [31]. At present, the relative abundance of vesicular or
carrier-based formulations for circ-miRs in the bloodstream is still
debated. Some reports suggest that the majority of circ-miRs are
exosome-borne [32], whereas others suggest that circ-miRs are pre-
dominantly vesicle-free and carried in protein- [33] or lipoprotein-
based complexes [34]. These discrepancies are probably due to still
different and rather incomparable methodologies of investigation.
However, following the notion of exosomes as miR carriers, a novellayer ofmiR-based cross-communication emerges on top of the conven-
tional intracellular regulations. Notwithstanding the lack of details
concerning putative receptors and intracellular processing, it has been
in fact reported that pre- or mature miRs are delivered to other cells
[35], where they exert their speciﬁc regulation (Fig. 1).
2.3. Artiﬁcial tools to regulate miRs
Oligonucleotides, i.e. miR-mimics and antagomiRs, can enhance or
repress endogenous miRs, respectively. MiR-mimics are artiﬁcial oligo-
nucleotides that are similar in sequence and possibly in secondary
structure to target pre-miRs. Once processed by the Dicer complex,
miR-mimics load the RISC complex with the query mature miR [36].
MiR-mimics are deliverable in vivo through lipid-based preparations,
which can however lead to unspeciﬁc uptake. Uptake speciﬁcity and
transduction efﬁciency are increased with viral vector formulations, yet
the issues of biodistribution and genome integration remain [37].
AntagomiRs are modiﬁed antisense oligonucleotides, competing with
the endogenousmiR formatching the target sequences. Also, antagomiRs
can interfere with pri-miR biogenesis, nuclear export, pre-miR matura-
tion and RISC loading. AntagomiRs are chemically enhanced with 2′-O-
methyl, 2′-O-methoxyethil or locked nucleic acid (LNA) nucleotides, in
order to improve stability and hence duration of the inhibitory effect.
AntagomiRs are deliverable in physiological-grade solutions, liposome-
or nanoparticle-based formulations, or as cholesterol-conjugated oligo-
nucleotides [38]. Noteworthy, an antagomiR has successfully passed a
phase-II clinical trial, in which the interaction between hepatitis virus C
and liver-expressed miR-122 was targeted. In this clinical study, pa-
tients received 5 weekly subcutaneous injections of the LNA-based
antagomiR in concentrations ranging from 3 to 7 mg per body weight
kg. Beneﬁcial effects on the viral RNA load appeared dose-dependent
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limiting adverse effects [39].
Another experimental tool of miR inhibition is the sponge, which
is an artiﬁcially overexpressed gene carrying multiple miR-binding
sites in tandem in its expanded 3′-UTR. Interestingly, sponges are par-
ticularly useful as they can inhibit up to a wholemiR family with similar
seed sequences [40]. Despite being highly variable in uptake and
modulation efﬁciency, miR-mimics and antagomiRs/sponges represent
attractive candidates to timely manipulate determined miRs during
the formation of cardiac and skeletal muscle both in vitro and in vivo,
at least in experimental and translational setups (Fig. 1).
3. Tissue engineering for striated muscles: room for miRs?
Striated muscle injury and degeneration account for signiﬁcant
fractions of adult mortality and disease burden worldwide. A notable
example thereof is the ischemic heart disease, which constituted the
ﬁrst cause of both mortality and burden over the last decade (WHO
Global Health Observatory, statistics related to 2000–2012). In addition,
genetically inherited chronic myopathies still cause a conspicuous, yet
unmet need for muscle tissue regeneration. In fact, the most severe
form of MD, the Duchenne MD, afﬂicts approximately 1 in 3000 young
males. Importantly, most MD forms feature chronic degeneration in
both striated muscle compartments, i.e. heart and skeletal muscles.
Therefore, the need for regenerative strategies for both muscle types is
still highly compelling.
At present, in order to reach this ambitious goal, several ﬁelds are
promisingly explored, including tissue engineering and stem cell-
based treatments.
Tissue engineering aims at supporting functional regeneration of
damaged striated muscles by means of generally three-dimensional
implants that combine biocompatible scaffolds with bioactive mole-
cules and/or stem cells [41,42]. Noteworthy for improving cardiac
functionality is the application of cell sheets or tissue slices on the peri-
cardium of damaged hearts. Myoblast cell sheets of ~100 μm thickness
have been applied on the left ventricle of hamsters with dilated
cardiomyopathy, resulting in maintenance of pre-operative values of
fractional shortening [43]. Furthermore, cardiac slices obtained from
adult or neonatal murine hearts have also shown promising results. In-
deed, application of 200/400 μm-thick cardiac slices on the left ventricle
of murine infarcted hearts resulted in improved ejection fraction at one
month post-transplantation [44]. In both approaches, host-driven re-
vascularization of the implant supports the hypothesis that paracrine
signals play a major role in the functional amelioration. However, the
implant-host cross exchange of resident progenitor cells and their fateTable 1
MiR manipulation strategies relevant for cardiac muscle repair/protection.
miR Target Means
⬆ miR-1/-133 Murine embryonic stem cells Lentiv
⬆ miR-1 Rat neonatal cardiomyocytes/murine adult heart Adeno
⬆ miR-499 Human CPCs Lentiv
⬆ miR-1/-499 Human fetal cardiomyocyte progenitors miR-m
⬆ miR-1/-499 Human embryonic stem cells Lentiv
⬆ miR-1/-133a/-208a/-499 Murine cardiac ﬁbroblasts miR-m
⬆ miR-499 Rat bone marrow mesenchymal stem cells Lentiv
⬇ miR-208a Rat adult heart (hypertension-induced hypertrophy) Antago
⬆ miR-21/-129/-212 Rat neonatal cardiomyocytes miR-m
⬆ miR-21 Rat adult heart (acute injury) Intraca
⬆ miR-138 Rat CPCs miR-m
⬆ miR-199a/-590 Rat/murine neonatal heart miR-m
⬇ miR-15 family Murine adult heart (acute injury) Antago
⬆ miR-24 Rat cardiomyocytes (ischemia-like conditions) miR-m
⬆ miR-21/-24/-221 Murine CPCs Lentiv
⬆ miR-22 Rat neonatal cardiomyocytes miR-m
⬇ miR-34a Human bone marrow mesenchymal stem cells Antago
The table concisely reports several experiments, and the related effects, of miR manipulation
strategies.regulation thereafter still remain largely unaddressed. In this regard, it
has been recently reported that an acellular matrix scaffold from por-
cine urinary bladder extensively mobilized and recruited perivascular
progenitors in injured skeletal muscles of animal models and human
patients. The colonized scaffold then counteracted the volumetric loss
of skeletal muscle with novel functional ﬁbers [45]. Albeit encouraging,
it is still unknown whether such approach can cope with the major
challenges of the upscaling and the hostile environment of chronically
myopathic muscles.
Tissue engineering for striated muscle repair often entwines with
stem cell-based treatments. In principle, transplantation of stem cells
aims at providing the degenerating muscle tissue with progenitors
able to engraft, to reconstitute genetically suitable myocytes and to re-
store, at least partially, the functionality. Main examples in such context
are cardiac stem cells for the heart and satellite cells for the skeletal
muscles. Cardiac stem cells, identiﬁed as c-Kit+ resident progenitors,
are clonally expandable and induce functional regeneration of ischemic
myocardium in animal models [46]. Moreover, autologous c-Kit+ cells
have shown safety and partial efﬁcacy outcome in a phase-I, random-
ized clinical trial [47,48]. In the skeletal muscle, satellite cells reside as
quiescent cells under the basal lamina and, in case of injury, proliferate
and potently regenerate damaged ﬁbers [49]. However, satellite
cells present a poor migratory potential when injected in the circula-
tion, therefore blunting their clinical translation at present. Although
intrinsically less committed, mesoangioblasts, i.e. resident myogenic
pericytes, appear a translational alternative for skeletal muscle re-
pair. Mesoangioblasts present, indeed, a high migration ability and
have been shown as promising candidates in small and large animal
models of MD [50,51]. Also, HLA-matchedmesoangioblasts are current-
ly under phase-I clinical study inMDpatients (EudraCT #2011-000176-
33). Recently, encouraging results for skeletal muscle engineering have
been obtained through implantation ofmesoangioblasts embedded in a
polyethylene glycol–ﬁbrinogen hydrogel. The implant was able to
mature into artiﬁcial, functional skeletal muscle ﬁbers in mice. Impor-
tantly, the cells were engineered to overexpress placental-derived
growth factor, and the implant was successful with both murine and
human mesoangioblasts [52]. With regard to the heart, myogenic
mesoangioblasts [53] or pericytes [54] have been recently isolated
also from the cardiac muscle, although their bench-to-bedside progres-
sion appears slower as compared to aforementioned cell systems.
Lastly, it is important to mention the growing interest around plu-
ripotent stem cells, both embryonic and induced, for striated muscle
(re)generation. Diverse approaches of differentiation and progenitor
cell sorting are currently available in literature [55,56], also in combina-
tionwith genetic engineering [57] or epigenetically biased systems [58].of manipulation Effects Ref
iral transduction ⬆ cardiomyogenic potential [66]
viral transduction ⬇ cardiac hypertrophic remodeling [67]
iral transduction ⬆ cardiomyogenic potential [70]
imic transfection ⬆ cardiomyogenic potential [71]
iral transduction ⬆ cardiomyogenic potential [72]
imic transfection ⬆ cardiomyogenic conversion [74]
iral transduction ⬆ cardiomyogenic conversion [75]
miR systemic delivery ⬇ cardiac hypertrophic remodeling [76]
imic transfection ⬆ cardiac hypertrophic remodeling [80]
rdiac adenoviral delivery ⬆ cardioprotection [81]
imic transfection ⬆ survival [88]
imic transfection/AAV systemic delivery ⬆ cardiomyocyte proliferation [90]
miR systemic delivery ⬆ cardioprotection [94]
imic transfection ⬆ survival (in vitro) [95]
iral transduction ⬆ survival (in vivo) [96]
imic transfection ⬆ cardiac hypertrophic remodeling [101]
miR transfection ⬆ survival (in vivo) [102]
in cardiac cells or in the myocardium, with potential relevance to cardiac regeneration
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feat the purpose of this review, it is of note for this work to highlight the
theoretical potential of pluripotent cells to give rise to different striated
muscle progenies [59]. However, issues such asmyogenic efﬁciency and
appropriate lineage commitment still currently hamper this potential,
particularly for in vivo applications [60].
It is thus imperative for present and future strategies of striatedmus-
cle tissue engineering to potentially overcome the hurdles imposed by
myogenic fate efﬁciency, topic survival rate and adverse signals from
the diseased niche. MiRs are emerging as key players in all three aspects
and, particularly, as tunable modulators of the myogenic program and
the adaptability of both exogenous and resident stem cells [11].
However, factual progress in miR-based strategies still relies on
unraveling the complexity of miRs in normal and pathologic contexts
of myogenesis. This review will therefore focus on the role of miRs in
experimental and translational settings of striated muscle de-/
regeneration, and on novel insights from the largely unexplored
ﬁeld of circulating miRs.
3.1. Cardiac myogenesis and miRs
Diverse miRs ﬁnely modulate cardiac myogenesis (Table 1). The
paramount role of miRs during cardiac muscle generation was ﬁrstly
highlighted by the severe cardiac defects that, together with other
major developmental aberrations, induced fetal lethality in Dicer-null
mice [61]. Themost abundant and investigatedmiRs involved in cardiac
myogenesis aremiR-1,miR-133,miR-208, andmiR-499, members of theFig. 2. Complexity ofmiR-based regulations in cardiacmyogenesis. This diagramdepicts a fractio
progenitor commitment and cardiomyocyte damage response. Genes are pseudocolored accord
process (arrows and squares). The same miRs can have different colors in accordance with the“myomiR” group [62]. These miRs have complex pleiotropic effects on
many aspects of cardiac myogenesis and muscle homeostasis (Fig. 2).
During cardiac development and maturation, miR-1 and miR-133
exert entwined spatiotemporal effects on expansion and terminal
differentiation of cardiac progenitor cells (CPCs). Excess ofmiR-1 limits
the expansion of cardiac progenitors by repressing Hand-2, while
miR-1-lacking murine embryos die at E10.5 because of severe cardiac
malformations [63].MiR-133a is fundamental for cardiac development
and CPC proliferation by targeting Cyclin-D2 and Srf in a negative feed-
back control [64,65]. Importantly,miR-1 andmiR-133a/b have also been
shown to enhance the differentiation of pluripotent cells towards the
mesodermal lineage. This has been assessed in murine embryonic
stem cells transduced with a lentiviral vector that induced expression
of both miRs at levels comparable to the endogenous miRs in the mu-
rine heart. The resulting increase of cardiomyogenic differentiation
was due to two parallel mechanisms. MiR-1 translationally repressed
the Notch ligand Dll-1, while miR-133 increased the proliferation of
CPCs [66]. Therefore, sustained levels of miR-1/-133 appear beneﬁcial
to the myogenic differentiation, albeit their modulation must be timely
appropriate and stage-speciﬁc. Also,miR-1 is downregulated in the dis-
eased heart and adenoviral-mediated overexpression ofmiR-1 (up to 5
fold endogenous levels) conversely attenuated hypertrophic remodel-
ing. This evidence was gathered in rat neonatal cardiomyocytes and in
adult murine hearts, where miR-1 represses Calmodulin and Mef-2a.
MiR-1-mediated effects were accordingly reverted in vitro in the
presence of 1 pmol cholesterol-linked anti-miR-1 [67]. Interestingly,
the mature forms of miR-1 and miR-133a are encoded from twon of themiRpathways commented on this review, to synthesize the information regarding
ing to their function (legend), whereas miRs are pseudocolored according to the cognate
different contexts in which they are depicted.
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miR-1-2/miR-133a-1 on chromosome 18 [68]. Srf andMef-2 transcription
factors, both MADS-box transcription factors regulating cardiomyogenic
regeneration, activate both miRs by recognizing speciﬁc enhancers [69].
Another important regulator of CPC maturation is miR-499. In
human CPCs, lentiviral-mediated overexpression of miR-499 by ~4000
fold endogenous levels depleted ~75% protein levels of targets Sox6
and Rod1, enhancing the cardiomyogenic progression. Transduced,
miR-499-overexpressing CPCs presented superior regenerative poten-
tial in vivo, once injected in infarcted hearts [70]. Moreover, particularly
in combination withmiR-1,miR-499was reported as direct regulator of
cardiomyogenic differentiation. Transfection of up to 100 nmol synthet-
ic pre-miR-1/-499 in human fetal cardiomyocyte progenitors resulted in
dose-dependent increase of differentiation efﬁciency at 12 days post-
treatment [71]. Furthermore, overexpression ofmiR-1/-499 precursors
by lentiviral transduction in human embryonic stem cells increased
target miR levels by ~30 fold and ~130 fold, respectively, across the
embryoid body stage and ameliorated in vitro cardiomyogenesis [72].
Remarkably, miR-499 has been implicated in junction-dependent miR
trafﬁcking, called “miRcrine mechanism”, between cardiomyocytes
and regeneratingCPCs, both in vitro and in vivo [73]. In addition, togeth-
er with the other myomiRs,miR-499 improves the direct conversion of
cardiac ﬁbroblasts into cardiomyocytes. Transfection of 50 nmol miR-
mimics of miR-1/-133a/-208a/-499 in murine cardiac ﬁbroblasts was
sufﬁcient to exert signiﬁcant changes on early cardiomyogenic markers
at 3 days post-treatment. Analogous effects were obtained on mature
differentiation markers at 7 days post-transfection. Accordingly, this
deﬁnedmiR signature is amenable also for conversion of endogenous ﬁ-
broblasts in vivo. Indeed, direct intramyocardial injection of 2 × 106
lentiviral units at two sites downstream of the coronary artery ligation
induced resident ﬁbroblasts to convert to cardiac cells and to contribute
to regenerated myocardium. In this study, the lentiviral vectors bore
themiR/reporter cassette under a promoter prominently active in ﬁbro-
blasts but not in other cardiac cells, strongly suggesting that the
cardiomyogenic conversion was ﬁbroblast-restricted [74]. Noteworthy,
miR-499 appeared sufﬁcient to stimulate the expression of cardiac fac-
tors, e.g. Nkx2-5, Gata-4 and cTnI, in rat bone marrow mesenchymal
stem cells through a positive loop with the canonical Wnt signaling.
This study relied on lentiviral-mediated miR-499 overexpression at
~16.5 fold levels vs control, and target gene levels were quantiﬁed at
3 days post-transduction [75]. However, these results were obtained
in vitro and further proofs are needed to establish their relevance
in vivo.
Genetically clustering with miR-499, miR-208a and miR-208b have
gained much attention as regulators of hypertrophic remodeling
and therefore as potential therapeutic targets. Remarkable for such per-
spective is that systemic delivery of LNA-enhanced anti-miR-208a
counteracted cardiac dysfunction in response to hypertension-induced
hypertrophy in rats. Administration of 25 mg/kg anti-miR-208a
appeared sufﬁcient to reduce miR-208a levels in the cardiac tissue by
~70% at 14 days post-injection. Intriguingly, analogous effects were ob-
tained through either intravenous, or intraperitoneal, or subcutaneous
delivery [76]. MiR-208a is embedded in one intron of Myh6, encoding
for α-Myosin heavy chain (α-MyHC), whereas miR-208b andmiR-499
are embedded in introns of Myh7 and Myh7b, both encoding for β-
MyHC. β-MyHC, characterized by a slower ATPase activity, is mainly
expressed in the fetal heart and upon hypertrophic adverse remodeling.
Conversely, α-MyHC is upregulated early after birth and accounts for
N90% of cardiacMyHC content in the adult heart. T3 signaling promotes
the expression ofMyh6 and miR-208a through a positive response ele-
ment, while inhibiting the expression of MyH7/7b and miR-208b/-499
through a negative element [77]. Upon cardiac stress, miR-208a binds
and represses T3 co-regulator Thrap-1, removing the transcriptional
block fromMyh7/7b loci, thereby promoting the switch to β-MyHC. Hy-
pertrophic remodeling is reinforced bymiR-208a-mediated repression
ofMyostatin [78]. Furthermore, once expressed together withMyh7/7bin the damaged myocardium,miR-208b and miR-499 target Sox-6, Pur-
β and Sp-3, known repressors ofMyh7, thus reinforcing the pathological
switch to the slow MyHC isoform [79]. Notable for translational
approaches relying on these miRs is that miR-208a-null mice did not
upregulate β-MyHC under stress, thus suggesting that miR-208a is
hierarchically upstream of miR-208b and miR-499 [78]. Therefore, the
molecular switch between miR-208a and miR-208b/miR-499 appears a
therapeutic target for the treatment of cardiac muscle hypertrophy.
Sustained inhibition of this switch is indeed a novel way to counteract
the adverse hypertrophic remodeling, which is a prominent complica-
tion in many chronic conditions of the heart.
3.2. MiRroring cardiac muscle diseases
Besides themiR-208a/miR-208b/miR-499 circuitry, other miRs have
been implicated in the aberrant switch to fetal programs in response
to cardiac stress. Transient pulse of 100 nmol pre-miR-21/-129/-212 in
rat neonatal cardiomyocytes caused hypertrophy and re-activation of
a fetal cardiac gene program at 48 h post-transfection. Moreover,
human fetal cardiac tissues and biopsies from end-stage heart failure
patients presented upregulation of these miRs, among others [80].
MiR-21, -129 and -212 hence appear part of a fetal miR signature that
is reactivated in the failing ventricular myocardium. These miRs share
many direct and indirect targets among cardiac differentiation or
remodeling genes [80]. Several studies have especially focused on
miR-21, reporting contrasting effects on cardiomyocyte survival and
cardiac ﬁbrosis. MiR-21 expression was found downregulated in the
myocardial infarct and upregulated in the border zone. Temporary
(10 s) perfusion of infarcted heartswith 200 μlmiR-21-bearing adenovi-
ral units resulted in reduction of infarct size by 29% at 24 h post-insult.
Moreover, the cardioprotective effect of miR-21 overexpression has
been linked to direct inhibition of one of its targets, Pdcd-4, which trig-
gers cardiomyocyte apoptosis [81]. However, a reciprocal loop between
miR-21 and Tgfβr-III, a negative regulator of Tgfβ signaling and collagen
deposition, has been proposed as possible infarct-triggered mechanism
for cardiacﬁbrosis [82]. OthermiRs potentially involved in cardiacﬁbro-
sis are miR-29 and miR-101 [83]. The miR-29 family is reduced after
acute myocardial infarction (AMI) and targets multiple factors involved
in the ﬁbrotic matrix, such as collagens, ﬁbrillins and elastin [84,85].
MiR-101a/b are also down-regulated after AMI, and their overexpres-
sion inhibited cardiac ﬁbroblast proliferation and collagen deposition,
by repressing cFos and Tgfβ1 pathways [86]. Manipulation of ﬁbrosis-
speciﬁc miRs is obviously palatable for post-AMI care. However, a
more reﬁned knowledge of the cell types interested by these miR net-
works will be fundamental to advance translational research on this
aspect.
A still puzzling example of fetal cardiac miRs playing a role in adult
cardiac stress is miR-138 [87]. It has been recently demonstrated that
miR-138 stimulates survival of a rat CPC cell line in conditions of hypoxia.
The study compared the effects on rat CPCs treated either with 50 nmol
pre-miR-138, or 100 nmol anti-miR-138, at 72 h post-transfection.MiR-
138-driven amelioration of survival appeared dependent on Mlk-3
targeting and the consequent repression of its downstream targets
Jnk/cJun [88]. To date,miR-138 is the only miR directly linked to cardiac
patterning and ventricle chamber formation. The developmental role of
miR-138 resides, at least partially, in the negative regulation of the
retinoic acid pathway. This negative loop leads to repression of Versican,
a cell adhesion molecule usually restricted to the atrioventricular canal
[89]. However, this evidencewas gathered in zebraﬁsh and the function
of miR-138 during mammalian development remains unknown. Al-
though miR-138 was also found upregulated in myocardial samples
from patients exhibiting congenital heart disease, further molecular
links are required in order to properly address the relevance of miR-
138 cardioprotective role in vivo.
A fetal trait potentially useful to counteract post-ischemic dysfunc-
tions is cardiomyocyte proliferation, which is also partly regulated by
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tiﬁed several miRs, includingmiR-199a andmiR-590, as robust inducers
of cardiomyocyte proliferation. These miRs induced ventricle hypertro-
phy and long-term resistance to permanent ligation of the coronary
artery. Intriguingly, intracardiac delivery of 2.8 μg mimics of human
miR-199a/590 in rat neonatal hearts after birth resulted in enlarged ven-
tricular wall without ﬁbrosis at 3 weeks of age. According experiments
were performed in neonatal mice after birth, through intraperitoneal
delivery of miR-bearing adeno-associated viruses (1011 AAV-9 units).
MiR-590 and -199a resulted overexpressed by ~250 fold and ~5 fold,
respectively, and signiﬁcant rates of proliferation of post-natal
cardiomyocytes, but not ﬁbroblasts, at 12 days of age were observed
[90]. Similarly,miR-17-92 familymembersmediate a similar phenotype
by targeting Pten [91]. These studies provide a promising genetic
evidence for putative applications, although a viral-free system of miR
delivery with sufﬁcient efﬁciency in vivo is still missing for human
cardiomyocytes.
3.3. MiRs involved in heart failure
Many miRs have been reported altered in conditions of heart failure
(Fig. 2). One common cause of heart failure is dilated cardiomyopathy,
which is common for the dystrophic myocardium [92]. Comparing
patients with dilated and ischemic cardiomyopathies, common trends
emerged, such as upregulation ofmiR-100 andmiR-195, and downregu-
lation of miR-92 and miR-133b [93].MiR-195 is of particular interest in
this context, asmiR-195-overexpressingmice display adverse hypertro-
phic remodeling leading to heart failure [77]. MiR-195 is part of the
broadly expressedmiR-15 family, whosemembers are variably involved
in cell proliferation regulation. Recently, LNA-enhanced antagomiRs
inhibiting miR-15 family components have been proven effective in
protecting against cardiac ischemic injury. Intravenous delivery of
0.5mg/kg and 1mg/kg antagomiRs inmice and pigs appeared sufﬁcient
to reduce the cardiac levels ofmiR-15 by ~72% and ~90%, respectively, in
conditions ofmiR-15-inducing cardiac stress. Interestingly, despite rapid
clearance from the blood stream after 12 h, antagomiR levels remained
detectable and effective for inhibition till 1 week post-injection. Also,
systemic delivery of 0.5 mg/kg anti-miR-15 oligonucleotides in mice
was associated with reduced infarct size and elevated cardioprotection,
and alleviated cardiac dysfunction after ischemia–reperfusion injury
[94]. Another non-muscle-speciﬁc miR involved in cardioprotection
against ischemia is miR-24, which targets the pro-apoptotic factor
Bcl2l-11. Immediately after experimental ischemia,miR-24was upregu-
lated in injured rat hearts. Also, miR-24 was interrogated in rat
cardiomyocytes cultured in ischemic-mimicking conditions (serum
starvation, hypoxia) by means of 100 nmol miR-mimic. Treated
cardiomyocytes presented an ~6 fold increase in miR-24 levels, and
reduced rates of in vitro apoptosis and necrosis. These ﬁndings and the
evidence that hypoxia-triggered Hif-1 activates miR-24 suggest thatTable 2
MiR manipulation strategies relevant for normal or aberrant skeletal myogenesis.
miR Target Means of manipulation
⬆ miR-1/-206 Murine satellite cells Adenoviral transduction
⬇ miR-1/-206 Murine neonatal skeletal muscles AntagomiR delivery
(systemic/intramuscular)
⬇ miR-1/-206 Murine pre-segmented embryos AntagomiR delivery
⬇ miR-27b Murine adult muscle (acute injury) AntagomiR delivery (intramus
⬇ miR-181 Murine myoblasts AntagomiR transfection
⬆ miR-214 Murine satellite cells Lentiviral transduction
⬆ miR-29 Murine myoblasts/rhabdomyosarcoma
cell line
miR-mimic transfection
⬆ miR-23a Murine adult muscle
(experimental atrophy)
Plasmid transfection
⬆ miR-669a Murine neonatal cardiac/skeletal muscles AAV2/9 delivery (intracardiac/
The table presents several cases and effects ofmiRmanipulation inmyogenic cells or skeletal m
aberrant or chronic disease conditions.miR-24 is part of a defective endogenous response enabled by hypoxic
cardiomyocytes, and that it is potentially targetable to improve survival
[95]. In addition, miR-24, miR-21 and miR-221 constitute a minimal,
deﬁned miR cocktail, amenable to improve survival in murine CPCs
both in vitro and in vivo. Combined transduction with single miR-
bearing lentiviruses, in fact, resulted in sustained CPC survival after
transplantation in both striated muscle compartments, according to
bioluminescence-based, non-invasive imaging. Consequently to the
longer survival in vivo, transduced CPCs showed also enhanced effects
on the functional outcome of injured hearts [96]. Furthermore, an
intriguing miR-regulated pathway in different heart failure etiologies is
the calcium ﬂux regulation. An example of such context is miR-214,
which was found upregulated in several conditions of heart failure and
hypertrophy. MiR-214 protects against excessive calcium uptake by
repressing a Na2+/Ca2+ exchanger (Ncx-1), a calmodulin-dependent
kinase (Camk-IIγ), a mitochondrial permeability modulator (Cypd),
and, once again, the pro-apoptotic Bcl2l-11 [97]. In the same context,
miR-133a has been recently linked to the calcium channel Ip3r-II in a
mutual repressive loop,which regulates calcium signaling and patholog-
ical cardiac remodeling [98].
MiRs can also target the myogenic remodeling by affecting key epi-
genetic regulators [99]. An example consists ofmiR-22, which promotes
hypertrophic remodeling in cardiomyocytes [100]. Transfection of rat
neonatal cardiomyocytes with 50 nmol miR-22-mimic resulted in
upregulated hypertrophic markers in both presence and absence of
phenylephrine, a hypertrophic agonist. Accordingly, genetic ablation
of miR-22 decreased cardiac hypertrophic remodeling in vivo. Targets
of miR-22 include the deacetylases Sirt-1 and Hdac-4, both involved in
the myogenic progression [101]. Sirt-1 is also targeted by another miR
involved in cardiac senescence and failure, miR-34a. Pre-treatment of
bone marrow mononuclear cells with 500 nmol LNA-enhanced anti-
miR-34a improved cell survival and engrafting capacity in vivo, in
experimental conditions of AMI [102]. Besides its effects on epigenetic
regulators,miR-34a targets anti-apoptotic Bcl-2 and cell cycle promoters
Cyclin-D2 and related kinases, thus promoting apoptosis and senescence
[103]. Considering the theoretical concerted repression of Cyclin-D2
exerted by miR-133a and miR-34a, it would be interesting to know
whether this holds true in cardiac regeneration and remodeling.
3.4. Skeletal myogenesis and miRs
A wide range of miRs tightly control skeletal muscle formation and
regeneration (Table 2). Similarly to the cardiac muscle, myomiRs play
a pivotal role in regulating myoblast commitment and skeletal muscle
formation [104]. MiR-1 promotes differentiation of cultured myoblasts
through translational repression of Hdac-4, which represses Mef-2-
dependent expression of myogenic factors [105,106]. Conversely, miR-
133 stimulates myoblast proliferation mostly through negative regula-
tion of Srf [107], thus creating a similar negative feedback loop asEffects Ref
⬆ skeletal myogenic differentiation [110]
⬆ proliferation of myogenic cells [110]
⬇ skeletal myogenic differentiation [111]
cular) ⬆ proliferation of myogenic cells [115]
⬇ skeletal myogenic differentiation [116]
⬆ skeletal myogenic differentiation [120]
⬆ skeletal myogenic differentiation [122]
⬇ skeletal muscle atrophy [136]
intramuscular) ⬇ skeletal myogenic aberrant conversion/differentiation [139,140]
uscle, with potential relevance to applications involvingmyogenic regeneration in normal,
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Mef-2,MyoD andMyogenin co-regulatemiR-1 andmiR-133 transcription
(Fig. 3). Importantly, in combination with Srf, MyoD activates miR-486,
which in turn represses Pten and FoxO-1a, reinforcing the Akt signaling
and enhancing muscle growth. Transgenic fate tracking showed that
miR-486 is expressed throughout somite-to-muscle formation stages
[108]. Hence, miR-486 appears an important link between MyoD and
the Akt signaling during skeletal muscle formation. This notion has been
recently explored through amiR-486-based transgenic system to counter-
act muscle wastage in a murine model of Duchenne MD [109].
A speciﬁc myomiR for the skeletal muscle is miR-206. Overexpres-
sion of miR-206 in combination with miR-1, by means of adenoviral
transduction, induced premature differentiation of primary murine
satellite cells, by targeting Pax7 3′-UTR. Conversely, administration of
80 mg/kg anti-miR-1/-206 in neonatal mice induced a signiﬁcant in-
crease of Pax7+/Brdu+ proliferating cells in the skeletal muscle at
24 h post-injection. Noteworthy, this effect was obtained at comparable
levels through both intramuscular and intraperitoneal delivery [110].
Furthermore, injection of antagomiRs targeting miR-1/-206 in pre-
segmentedmurine embryos resulted in dramatically decreasedMyogenin
expression and perturbedmyogenic development. This effect was traced
to the ability ofmiR-1 andmiR-206 to bind two conserved regions on the
3′-UTR of Pax3, a myogenic factor sustaining the myoblasts in an imma-
ture state [111]. MyoD and Myogenin recognize miR-206 upstream
enhancer and activate its expression.MiR-206 promotes myoblast differ-
entiation by repressing many targets, including Pola-1, the largest DNA
polymerase subunit, thereby halting the proliferation machinery in
favor of differentiation [112]. In addition,miR-206 targets gap-junctionFig. 3. Complexity of miR-based regulations in skeletal myogenesis. This diagram depicts severa
differentiating muscle progenitors and diseased skeletal ﬁbers. Genes are pseudocolored accor
process (arrows and squares). The same miRs can have different colors in accordance with theCx43 [113], hence putatively promoting the terminal maturation of
skeletal ﬁbers. Also, miR-206 has been implicated as regulator of a
spontaneously mutated Myostatin 3′-UTR, likely causing muscle mass
overgrowth in the Belgian Texel sheep [114].
Analogously to the cardiac muscle, myomiRsmiR-208b andmiR-499
are upregulated also in slow skeletal muscle ﬁbers followingMyh7/7b
expression, and reinforce the switch to β-MyHC in the presence of
calcium-related ﬁber stress [79].
Subsequently to the exit from the proliferative state, miR-27b and
miR-181 contribute to prime the differentiating cells along later stages
of skeletal myogenesis. MiR-27b further promotes progression of the
differentiation by translationally repressing Pax-3. Lentiviral-mediated
miR-27 overexpression in somite explant cultures drastically reduced
Pax3+ and increased Myogenin+, committed progenitors. Accordingly,
intramuscular injection of 10 μmol anti-miR-27b upon acute muscle
injury resulted in increased number of Pax3+ satellite cells. As a conse-
quence, themuscle regeneration appeared delayed, although the effects
were quantiﬁed at a rather early stage (6 days) post-injury [115].
Similarly, miR-181 indirectly activates MyoD by targeting one of its
negative regulators, HoxA-11. Transfection of murine myoblasts with
miR-181-targeting antagomiR, in fact, affected in vitro myotube forma-
tion. However, it is intriguing to note that, in the same experimental
model, miR-181-mimic was not altering myoblast differentiation. This
suggests that the endogenous levels ofmiR-181 are normally sufﬁcient
to reach effect-exerting plateau [116]. Other regulators of the balance
between proliferation and differentiation in myogenic cells are miR-322
and miR-503, which target cell cycle promoter Cdc-25a, although the
evidence is at present limited to one myoblast cell line in vitro [117,118].l pathways presented in this review, in order to synthesize the information gathered from
ding to their function (legend), whereas miRs are pseudocolored according to the cognate
different contexts in which they are depicted.
Table 3
Relevant miRs and targets in cardiac and skeletal myogenesis.
miR Reported target genes
in cardiac myogenesis
Reported target genes
in skeletal myogenesis
Ref.
miR-1 Calmodulin; Dll-1;
Hand-2;Mef-2a
Hdac-4; Pax-3; [63,66,67,
105,111]
miR-17-92 Pten [91]
miR-21 Pdcd-4; Tgfβr-III [81,82]
miR-22 Hdac-4; Sirt-1 [101]
miR-23a Atrogin-1;Murf-1 [136]
miR-24 Bcl2l-11 [95]
miR-27 Pax-3 [115]
miR-29 Col1-a1; Col1-a2; Col3-a1;
Eln-1; Fbn-1;
Rybp
Yy-1
[84,122,
123]
miR-34a Bcl-2; Cyclin-D2; Sirt-1 [102,103]
miR-101 cFos; Tgfβ1 [86]
miR-133 Cyclin-D2; Ip3r-II; Srf Maml-1;Mef-2c; Srf [64,65,98,
107,125]
miR-135 Maml-1;Mef-2c [125]
miR-138 Aldh1-a2; Cspg-2;Mlk-3 [88,89]
miR-181 HoxA-11 [116]
miR-199a Clic-5; Homer-1; Hopx [90]
miR-206 Cx43;Myostatin
(mutated);
Pax-3; Pax-7; Pola-1
[110–114,
124]
miR-208a Myostatin; Thrap-1 [77,78]
miR-208b Pur-β; Sox-6; Sp-3 Pur-β; Sox-6; Sp-3 [79]
miR-214 Bcl2l-11; Camk-IIγ;
Cypd; Ncx-1
Ezh-2 [97,120]
miR-486 FoxO-1a; Pten [108]
miR-499 Pur-β; Rod1; Sox6; Sp-3 Pur-β; Sox-6; Sp-3 [70,79]
miR-590 Clic-5; Homer-1; Hopx [90]
miR-669a/q MyoD (aberrant switch) MyoD [139,140]
The table summarizes several miRs and related target genes as reported throughout the
review.
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trols are complexly entwined with miRs in skeletal muscle formation
[119]. An example of miRs driving indirect epigenetic regulation is
miR-214. Lentiviral-mediated overexpression of miR-214 up to ~5 fold
endogenous levels increments the number of Myogenin+ differentiat-
ing cells in primary cultures of myoﬁber-derived satellite cells. MiR-
214 positively regulatesMyogenin, Ckm (creatine kinase, CK) and Myh
(myosin heavy chain) by targeting their negative epigenetic regulator
Ezh-2,member of the Polycomb repressive complex [120]. This regulation
seems important for normal skeletal muscle development, as transgenic
ablation of miR-214 results in embryonic lethality and severe skeletal
muscle defects [121]. Yet an example of miR-epigenetics feedback loop
is highlighted by the case of the pro-myogenic miR-29. Transfection of
50 μmol pre-miR-29 oligonucleotides, but not the mutated control, in-
creased expression up to ~3000 fold basal levels and associated with
higher expression of terminal markers of skeletal myogenesis in murine
myoblasts. Intriguingly, the same treatment appeared effective also on
rhabdomyosarcoma cell lines, which consequently displayed slower
rates of growth. Downstream of NF-κB circuitry,miR-29 is repressed by,
and in turn represses, chromatin remodelers Rybp and Yy-1 [122,123].
Conversely, alternative polyadenylation and long-noncoding RNAs
constitute two possibilities of reﬁned post-transcriptional control on
myogenicmiR activity. In the ﬁrst case, a reported example is the alterna-
tive polyadenylation of Pax-3, which presentsmiR-206 target site at its 3′-
UTR only after the onset of differentiation [124]. In the second case, linc-
MD1 serves as competing sponge to titratemiR-133 andmiR-135 away
from their targets,Maml-1 andMef-2C, further allowing myoblast differ-
entiation [125]. Intriguingly,Maml-1 andMef-2C have been reported as
important fate regulators also in human mesoangioblasts [126]. This
notion opens the enticing question whether linc-MD1might represent a
novel target to enhance the potential of myogenic cells amenable for
systemic delivery. However, to address this translational perspective,
molecular tools to modulate long-noncoding RNAs must ﬁrst be reﬁned
and upscaled.
3.5. MiRroring skeletal muscle diseases and fate switch
Chronic muscle disorders disrupt miR circuitries, raising the in-
triguing possibility of disease-speciﬁc miR signatures traceable in
muscle biopsies [127]. This point would be particularly useful to
help physicians and biologists in discriminating between the diverse
forms of chronic myopathies and dystrophies, often mistaken with-
out the support of a complete genetic screen. In this regard, miR-
299-5p, -487b, -362 have been reported as speciﬁcally upregulated in
DuchenneMD,whereas inﬂammatorymiR-155, -146bwould character-
ize inclusion body- or dermato-myositis. Moreover, miR-381, -382
would mark the facioscapulohumeral MD, and miR-100, -103, -107
would hallmark limb-girdle MDs when compared to Duchenne MD
[128,129]. Analogously, miR signatures potentially characterizing
sarcopenia are intensively investigated, for instance during aging [130,
131]. In mice, it has been reported that miR-7/-206/-468/-542/-698 are
upregulated in aged muscles, whereas miR-124a/-181a/-221/-382/-
434/-455 are upregulated in adult controlmuscles [132].When compar-
ing muscle miR signatures between old and young individuals in
primates, it has been reported that aged muscles presented downregu-
lation of miR-181a and upregulation of miR-15a/-18a/-144/-451 [133].
Despite the quantitative differences, further experiments are required
to pinpoint the downstream targets and the biological role of such
signatures. Interestingly, in human muscles, not only did mature miRs
exhibit differential expression upon aging, but also pri-myomiRs, e.g.
pri-miR-1 and pri-miR-133a, presented higher levels [134,135]. This
evidence opens the question whether the pri-miR accumulation in
elderly muscles is due to deﬁciencies in the maturing machinery or to
aging-speciﬁc cues.
In addition to aging, muscle atrophy also causes muscle mass loss,
often as a consequence of chronic diseases. In this context, miR-23aplays an important role, as dexamethasone-induced atrophy of mu-
rine adult skeletal ﬁbers is attenuated after transient pulse of a
miR-23a-expressing plasmid. Consistently, miR-23a-overexpressing
mice displayed resistance to dexamethasone-induced atrophy. It has
been shown that miR-23a targets the 3′-UTR of both Atrogin-1 and
Murf-1, which mediate atrophy-associated protein degradation [136].
A fascinating perspective for miRs in striated muscle control resides
in their role in myogenic fate switches. Murine dystrophic cardiac
mesoangioblasts presented the aberrant propensity to differentiate
into skeletal muscle ﬁbers, which were functionally uncoupled from
the surroundingmyocardium and contributed to progressive exacerba-
tion of the dilated cardiomyopathy [137,138]. The pathologicalmyogen-
ic switch has been imputed tomiR-669a/q. Indeed, transduction of the
neonatal murine myocardium with miR-699a-expressing AAV2/9, but
not with scramble-bearing AAV, resulted in traceable, life-long miR
overexpression (~6 fold endogenous levels at 18 months of age) and
partially alleviated end-stage dystrophic cardiomyopathy [139]. MiR-
669a/q are negative regulators ofMyoD and are repressed in Sgcb-null
murine cardiac mesoangioblasts, owing to two concerted mechanisms.
MiR-669a lies within the intron 10 of Sfmbt gene, whereas intron 1 of
Sgcb harbors miR-669q. Transgenic deletion of Sgcb expression confers
the dystrophic phenotype and ablates expression of miR-669q. In addi-
tion, intracellular calcium leakage, typical for dystrophic myocytes,
causes degradation of Yy1, activator of Sfmbt, and downregulation of
miR-669a [140]. Albeit a direct human ortholog of miR-669a/q is still
unidentiﬁed, MYOD re-expression in cardiac cells was reported for
two subjects with oncocytic cardiomyopathy [141], thus opening the
question of which miRs can be targeted to counteract pathological
myogenic switches in patients.
3.6. MiRs, not miRacles: hints from and for regenerative medicine
In order to translate the ﬁndings about miRs and related targets
(Table 3) into clinical-grade solutions for striated muscles, it will be
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in vivo effects of miR-based strategies.
The aforementioned systemic delivery of anti-miR-208a is a brilliant
example of a therapeutic approach with beneﬁcial effects restricted to
the heart, without reported side effects in the skeletal muscle or
in other districts [76]. Although it remains unknown whether such
approach is upscalable to humans, its successful outcome is likely due
to the natural properties ofmiR-208a and to the intrinsic characteristics
of the disease model. MiR-208a is cardiac-speciﬁc and prominently
down-regulated after birth, and it is generally re-activated only under
pathological remodeling [77]. Moreover, hypertension-prone Dahl rats
do not present evident damage in the skeletal muscles [142]. Converse-
ly, when miRs can act in both striated muscle types, their modulation
must be conﬁned to the desired district. An example ismiR-669amanip-
ulation, which induced beneﬁcial effects in the degenerating heart, but
also a potentially negative response in regenerating skeletal ﬁbers
[140]. In that respect,miR-206 could be a candidate miRNA for a thera-
peutic approach focused on the skeletal muscle compartment, owing to
its rather speciﬁc targets. However, before approaching strategies of
miR-206modulation by means of systemic delivery, it will be primarily
important to exclude that miR-206 can induce any aberrant fate
switches in resident cardiomyogenic cells.
Other approaches that should be considered for therapeutic ad-
vances, possibly in combination, are the multimodal miR modulation
and the timely delivery. Multimodal miR modulation consists of com-
bining up- and downregulation of different miRs in the same regenera-
tive strategy. Although obviously more difﬁcult to optimize, owing to
often divergent miR-speciﬁc requirements, such approach would theo-
retically increase speciﬁcity and efﬁcacy of systemic deliveries. In that
respect, it might be interesting to combine the modulation of myomiRs
with survival-enhancing miRs in cardiac-oriented strategies, and with
epigenetics-regulating miRs in skeletal-oriented strategies. Particularly
with regard tomyomiRmodulation, time-speciﬁc dosageswill probably
increase the applicative potential of translational strategies. Consistent-
lywith this notion, it will be useful to determine relative time sequences
for the modulation of miR-1/-133/-499, in combination with either
miR-208a, as cardiac-speciﬁc, or miR-206, as skeletal muscle-speciﬁc.
Moreover, timely modulation of different myomiRs might be applied
to systemic approaches in vivo, considering the transient effects and
the rapid clearance of miR-mimics or antagomiRs. Such in vivo strate-
gies will be particularly relevant when addressed in appropriate animal
models of acute or chronic muscle damage. Reﬁnement of these studies
will likely enable us to better articulate the myomiR-driven regenera-
tive response in the two striated muscle types.
A critical point for progressing miRs as pharmaceutical tools in the
regenerative medicine for striated muscle is the means of miR modula-
tion. Notwithstanding recent advances in conjugation and chemistries,
oligonucleotides still appear mainly ideal for applications limited in
time, owing to short half-life after systemic delivery and often problem-
atic upscaling. AAVs, especially considering the tropism of serotypes 2
and 9 for striated muscles, are experimentally rather potent and ensure
miR-modulation on the long term. However, their clinical application
appears presently blunted, due to the risks posed by random genomic
insertions [143]. In this regard, a putative alternative could be the
combination of tissue engineering and miR modulation technologies.
Appropriate stem cell pools, possibly with scaffolds enhancing their
survival and commitment, might be engineered as in vivo paracrine
hubs of miR modulation. The cell implant would then provide the
host tissue with speciﬁc beneﬁcial miRs or anti-miRs. Importantly,
the choice of the stem cell pool will potentially inﬂuence speciﬁcity
and directionality of miR modulation in host cell types. This has indeed
been reported in the opposite direction for the miRcrine cross-talk
between cardiomyocytes and cardiac stem cells [73].
Lastly, translational research on miRs governing striated muscle
regeneration will deﬁnitely take advantage of a deeper understanding
of the cell-to-cell patterns and the causal relationships between miRsand downstream biological effects. In this perspective, a necessary
path will consist of interrogating the complex regulation/effects of
circulating miRs in experimental models and clinical cases of striated
muscle regeneration. Therefore, the last part of this review will focus
on the rapidly expanding ﬁeld of exosome-borne and circulating miRs
(circ-miRs).
4 . Exosomal and circulating miRs in striated muscle regulation
4.1. Exosomes: a novel route of miR-based signals for cardiac muscle
regulation
The role of exosomes as signaling shuttles for short- and long-range
communication between cells and striated muscle tissues has recently
emerged (Figs. 2–3). In the plasma of healthy individuals, exosomes
are present in a surprisingly high concentration (~1010/ml) [144], sug-
gesting a physiological signaling role beyond the pathological shedding
of cell debris. Exosomal cargo may contain proteins, mRNAs and miRs,
and accumulating evidence is implicating exosomal miRs in a variety
of cardiac and skeletal muscle conditions.
Since the ﬁrst ultrastructural evidence of exosome secretion by CPCs
and cardiosphere-derived cells (CDCs) [145], several other studies have
reported on exosomal miRs inﬂuencing cardiomyogenic cell behavior.
In vitro, rat CPCs have been shown to secrete exosomes enriched in
miR-133a after cell death induced by calcium ionophore treatment.
Exosomal miR-133a resulted functionally transferred to non-cardiac
cells [146]. In vivo, CPC-derived exosomes, enriched in miR-451, signif-
icantly decreased cardiomyocyte apoptosis in AMI, likely through re-
pression of Caspase3/7 [147]. In addition, exosomes have been shown
to mediate CDC-driven regenerative effects in the heart, partly by shut-
tling miR-146a [148]. Furthermore, exosomes have been implicated in
an experimental model of cardioprotective ischemic preconditioning.
This model consists of brief insults in remote myocardial areas to ame-
liorate the outcome of subsequent sustained ischemia [149]. Moreover,
exosome-borne miR-22 has been demonstrated to partly mediate the
cardioprotective effect of ischemic preconditioning by targeting the
epigenetic regulatorMecp-2 [150]. Mecp-2 exerts pleiotropic effects on
several factors regulating survival or apoptosis, although this has current-
ly been demonstrated only in non-muscle contexts [151–153]. These
observations partially match previous ﬁndings showing the exosome-
mediated beneﬁcial effects of human mesenchymal cells on ischemia/
reperfusion injured myocardium [154]. Conversely, resident miRs can
also be regulated by exosomal proteins/transcripts, as it has been report-
ed for Sca-1+ CPCs shuttling Hsf-1 into ischemic cardiomyocytes, lead-
ing to epigenetic repression ofmiR-34a and improved survival [155].
Exosomes are probably involved in shuttling circ-miRs between dif-
ferent tissues in pathological conditions. Increased levels of circ-miR-1
and -miR-208 were found in the urine of AMI-affected rats. These circ-
miRs have been linked to exosome shuttling from the injured heart
through the kidney [156], although the observation was gathered from
re-injection of exosomes in the animals. Recently, ﬁbroblast-derived
exosomal miR-21* has been identiﬁed as a pro-hypertrophic factor in
cardiomyocytes, where it represses Sorbs-2 and Pdlim-5 [157]. Further-
more, circ-miR-214 was found altered in CAD patients [158]. It has also
recently been shown that miR-214 constitutes a fundamental part of
the cargo of pro-angiogenic exosomes secreted from endothelial cells
[159]. However, a direct proof of functional uptake of endothelial-
borne exosomal miRs by injured myocardial cells in vivo is still missing.
4.2. Exosome-borne miRs for skeletal myogenesis regulation
Exosomal miRs are attracting increasing levels of attention within
the context of skeletal myogenesis. In fact, engineering pharmacological
or stem cell-mediated formulations of targeted exosome-borne miRs
constitutes an enticing translational perspective for enhancingmyogen-
ic regeneration [160]. In support of this speculation, CD34+ stem cells
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ing agonist Shh, which has pro-angiogenic effects. Functional transfer of
Shh was evident in vitro. Moreover, after injection of the engineered
CD34+ cells in the border zone, themyocardial infarct sizewas reduced,
the capillary density was increased, and the functionality resulted
improved on the long term [161]. Furthermore, artiﬁcial formulations
of exosomes carrying speciﬁc miRs have already been successfully
tested to target the murine brain after systemic delivery [162]. A fasci-
nating putative path will consist of combining speciﬁc exosomal-miR
formulations with transmembrane signaling proteins able to interact
with the endogenous myogenic stem cells, such as Notch ligands [126,
163]. In line with this idea, a feedback circuitry involving miR-126
and Dll-4 in mesenchymal stem cells has already been linked to pro-
angiogenic remodeling in the ischemic myocardium [164].
Of potential signiﬁcance for the translational concept of stimulating
resident progenitors is the notion that myoblasts secrete exosomes
[165], although with different content types and effects during the pro-
liferation and the differentiation stages in vitro [166]. Myotube-derived
exosomes, in fact, promoted differentiation of target myoblasts by
down-regulating Cyclin-D1 and Myogenin [167]. Yet the question
remains of whether miR-186, -329 and -362 are involved, as these are
predicted binders of the 3′-UTRs of both genes. Intriguingly, using the
same myoblast model, atrophic myotubes presented decreased intra-
cellular levels, but increased exosomal fractions of miR-23a [168] and
miR-182 [169]. This observation suggests a selective exosome-loading
of miRs under stress conditions. Despite being promising, the ﬁeld of
exosomal miRs in skeletal myogenesis will deﬁnitely need more
exhaustive investigation in a wider range of muscular disorders and
regenerative strategies in vivo.
4.3. Circ-miRs: biomarkers and/or effectors in the context of cardiac
damage?
During the last decade, evidence has accumulated from animal
models and clinical studies, pointing at circ-miRs as novel biomarkers
of the striated muscle condition. Circ-miR levels in serum and plasma
are indeed readily detectable and appear altered in a variety of condi-
tions. Although many issues must still be overcome, particularly in
terms of sensitivity and feasibility [170,171], circ-miR analysis could in
principle improve the presently used diagnostic or prognostic tools.
Indeed, circ-miRs, especially as signatures, might help in focusing the
current diagnostic tools, such as circulating CK, myoglobin or troponins,
often altered by issues unrelated to the striated muscle pathology
[172,173]. When approaching this exciting body of literature, however,
an important caveat to consider is the still substantial lack of experi-
mental evidence discriminating between the circ-miRs effecting a
signal and the circ-miRs derived from an affected muscle.
Several studies have linked the circulating levels ofmiR-1, the most
abundant miR in striated muscle, with acute or chronic conditions of
muscle damage [174]. Indeed, the ﬁrst evidence of increased plasma
levels of circ-miR-1 in AMI patients [175] was consolidated by pre-
clinical studies, documenting circ-miR-1 time peaks in AMI animal
models. Serum levels of circ-miR-1 correlated with release of the
cardiac-speciﬁc CK isoform and with infarct size [176].
Circulating levels of myomiRs were found signiﬁcantly increased in
the aortic ﬂow and correlated with serum levels of troponin-T (current
standard of indirect measurement of myocardial damage) in acute cor-
onary syndrome (ACS) patients, when compared to troponin-negative
patients with coronary artery disease (CAD). Intriguingly, this study
also reported that endothelium-enriched miR-126 inversely correlated
with the extent of myocardial injury, suggesting that miR-126 is
consumed during the trans-coronary passage through either uptake or
turnover [177].
Further possible implications of these ﬁndings relate to the role of
miR-499 in hypertrophic cardiac remodeling [178] and on the complex
vascular regulations exerted by miR-126. Indeed, miR-126 stimulatesangiogenesis by repressing Spred-1 and R2-p58β, negative regulators
of the Vegf signaling [179]. MiR-126 also decreases inﬂammatory cell
recruitment and extravasation by repressing Vcam-1 [180]. Accordingly,
plasma levels of circ-miR-1 and -miR-126 have been reported as in-
creased and decreased, respectively, at 4 h after the onset of symptoms,
when comparing AMI patients to healthy control subjects [181]. The
paracrine effects of miR-126 have also been documented in CD34+
cell-derived exosomes, which improved post-ischemic conditions by
stimulating angiogenesis [182,183]. In this regard, it is intriguing to
note that diabetes mellitus patients displayed CD34+ cells with im-
paired paracrine functions and that miR-126 overexpression was able
to revert their dysfunctionality [184]. Thus, this evidence links the
known neovascularization defects of diabetes mellitus to cardiac cells
by means of miR-bearing exosomes. Another recent study of miR-
based trans-coronary biomarkers identiﬁed miR-423-5p as a cardiac-
speciﬁc heart failure plasma marker, positively correlating with the b-
type natriuretic peptide [185]. Interestingly, miR-423-5p has also been
reported, in combination with miR-499, as a putative biomarker dis-
criminating congestive heart failure from AMI [186].
Members of themiR-133 andmiR-208 families have also been inves-
tigated as circulating biomarkerswith potential diagnostic andprognos-
tic value. Circ-miR-133a/b and -miR-208a/b were increased in the
plasma of a large cohort of ACS patients. Intriguingly, higher levels of
miR-133b and miR-208b apparently correlated with adverse prognosis
[187]. In another study conducted on myocardial infarct patients
undergoing primary angioplasty, circ-miR-133a levels associated with
larger infarcts, higher reperfusion injury and decreased myocardial
recovery [188]. Plasma concentration of circ-miR-208a resulted aug-
mented in rats after isoproterenol-induced myocardial injury, but not
in rats with cardiac hypertensive hypertrophy. This suggests that circ-
miR-208a is probably linked directly to the cardiomyocyte wastage
and that hypertrophy is not per se sufﬁcient to promote circ-miR-208a
leakage [189]. In addition, circ-miR-208a appears to be a more sensitive
biomarker of the early phase of AMI, particularly within the ﬁrst 4 h
after onset [190].
4.4. Circ-miRs in the context of skeletal muscle damage and physical
exercise
Circ-miRs are currently also being scrutinized in relation to skeletal
muscle disorders [191]. Serum levels of circ-myomiRs (miR-1, -133a, -
206) were found to be increased in both murine and canine models of
DuchenneMD [192]. Interestingly, circ-myomiR levels appeared to corre-
late with disease progression and were poorly inﬂuenced by physical or
muscle-unrelated stress [193]. Upregulation of these circ-miRs has
also been documented in Duchenne MD patients, when compared to
age-matched subjects [194,195]. Circ-miR-206 has been proposed as a
biomarker for amyotrophic lateral sclerosis following plasma mea-
surements in a murine model of the disease [196]. Furthermore, circ-
myomiR perturbations have been reported for patients with chronic
obstructive pulmonary disease [197], which often display muscle
atrophy, and in patients bearing rhabdomyosarcoma tumors [198]. In
addition, increased circ-miR-144 has been associated with insulin-
resistance in skeletal muscles of diabetic animals and patients [199].
Muscle-related circ-miRs seem appear to be affected not only by the
pathological state, but also by physiological activities such as physical
exercise. Time-dependent changes in several circ-myomiRs have been
observed during recovery from exercise [200]. The type of exercise in-
ﬂuences the entity of ﬁber damage and muscle response, and circ-miR
levels might reﬂect these changes. Plasma myomiR levels indeed in-
creased after muscle-damaging eccentric exercise, i.e. marathon run-
ning, but not after concentric exercise, i.e. prolonged biking [201,202].
In addition, a growing body of literature is dedicated to the differences
in circ-miRs with respect to the training status preceding diverse
exercise modalities [203]. These studies are apparently pointing at
circ-miRs as ﬁne diagnostic biomarkers of pathological remodeling
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exclude the possibility of a defective circ-miR-based signaling, aimed
at eliciting survival and adaptation in non-degenerating ﬁbers. Impor-
tantly, both contribution and response are still rather poorly distin-
guishable between cardiac and skeletal muscles in these studies. Thus,
further steps towards a systematic evaluation of causality relations are
required to disentangle the complex web of circ-miRs.
5. Future perspectives and conclusions
In conclusion, investigation into miR-based feedback circuitries has
clearly enriched our current understanding on the myogenic processes
during striated muscle speciﬁcation. Both for cardiac and skeletal myo-
genic routes, miRs have emerged as reﬁned and potent tools to direct
many gene pathways towards a detrimental or beneﬁcial outcome
[204]. Still, more work is required to determine how the miRNA inter-
play critically affects different facets of the myogenic lineage commit-
ment and the adult muscle remodeling. Studying miRNA ﬂuctuations
in biomaterial-embedded stem cells would certainly be useful in reﬁn-
ing our tools for ex-vivo myogenesis, and in boosting clinical applica-
tions. Indeed, the combination of cell-based tissue engineering with
dedicated miRNA modulation could be an avenue with potential
therapeutic value for striated muscle repair.
Furthermore, through either exosomes or protein carriers, circ-miRs
are emerging as possible mediators of long-range biological effects, and
as putative biomarkers for more comprehensive diagnoses and progno-
ses. However, more efforts are needed to shed light on the still numer-
ous open questions. In particular, it will be mandatory to address the
directionalities and the causal relationships of miR-based circuitries on
a cellular level. Following this perspective, it will be intriguing to
decipher how miRs affect the interplay between different cell and
stem cell types involved in striated muscle (re)generation. In this
context, the combination of induced pluripotent stem cells and next-
generation sequencing will be of great beneﬁt in modeling the diverse
myogenic cell players, and in unraveling the cross-signaling miR
cascades.
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